Renalytix to Present at Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Renalytix plc (NASDAQ: RNLX) announced their participation in the Cowen 42^nd Annual Health Care Conference, set for March 9, 2022, at 10:30 a.m. EST. The event will feature a fireside chat with the company's management and will be accessible via a live and archived webcast on their investors' website. Renalytix specializes in bioprognosis for kidney health, with their leading product, KidneyIntelX, receiving Breakthrough Designation from the U.S. FDA to enhance diagnosis and management of kidney disease.

NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming virtual Cowen 42^nd Annual Health Care Conference.

Renalytix’s management is scheduled to participate in a fireside chat on Wednesday, March 9, 2022, at 10:30 a.m. EST. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at investors.renalytix.com. The company will also be available for virtual 1X1 meetings with investors registered for the event.

About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage CKD progression risk assessment. The Company’s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

For further information, please contact:

Renalytix plc			www.renalytix.com
James McCullough, CEO			Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)			Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)			Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth		Mob: 07980 541 893 / 07584 391 303
CapComm Partners
Peter DeNardo			Tel: 415-389-6400 or investors@renalytix.com

FAQ

When will Renalytix present at the Cowen 42nd Annual Health Care Conference?

Renalytix will present on March 9, 2022, at 10:30 a.m. EST.

How can I access the Renalytix conference presentation?

The presentation can be accessed via a live and archived webcast on Renalytix's investor website.

What is the main focus of Renalytix at the Cowen Conference?

Renalytix will focus on their advancements in bioprognosis for kidney health and their product KidneyIntelX.

What is KidneyIntelX and its significance?

KidneyIntelX is a product of Renalytix designed to improve kidney disease prognosis and has received U.S. FDA Breakthrough Designation.

What stock symbol is associated with Renalytix?

Renalytix is traded under the stock symbol RNLX on NASDAQ.